**Core Concept**
The question requires understanding of **hematological malignancies**, specifically **lymphoproliferative disorders**. The key concept here is the identification of **B-cell lymphomas** using **flow cytometry** and **immunophenotyping**.

**Why the Correct Answer is Right**
The presence of **CD19+**, **CD5+**, and **monoclonal B-cells** with **bright kappa positivity** is characteristic of **Chronic Lymphocytic Leukemia (CLL)**. However, CLL typically expresses **CD23**. The absence of **CD23** and the specific immunophenotypic profile point towards **Mantle Cell Lymphoma (MCL)**, which is a distinct entity. MCL cells are **CD5+**, **CD19+**, and often express **bright light chain restriction**, in this case, **kappa positivity**.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because the description does not match the typical immunophenotype of the option.
**Option B:** Incorrect as it does not align with the provided immunophenotypic characteristics.
**Option C:** Incorrect because the specific details do not correspond to this option.

**Clinical Pearl / High-Yield Fact**
It's crucial to remember that **Mantle Cell Lymphoma** often presents with **lymphadenopathy**, **splenomegaly**, and a **high white blood cell count**, and its diagnosis relies heavily on **immunophenotyping** and **cytogenetic analysis**, particularly the **t(11;14) translocation**.

**Correct Answer:** D. Mantle Cell Lymphoma.